Vascepa二十碳五烯酸乙酯 icosapent ethyl

Drug Class

Purified omega-3 fatty acid / Ethyl ester of eicosapentaenoic acid (EPA)

Mechanism

Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA) that reduces hepatic triglyceride synthesis and enhances clearance from circulating lipoproteins.

Approved Indication

Reduction of cardiovascular risk in adults on statins with elevated triglycerides (>=150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors, or severe hypertriglyceridemia (>=500 mg/dL).

What This Means For Patients

Vascepa二十碳五烯酸乙酯 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2012) — Sources
• EMA — Approved (2021) — Sources
• NMPA — Approved (2023) — Sources

Pivotal Clinical Evidence

• REDUCE-IT — Bhatt et al., N Engl J Med 2019 (NCT01492361) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s019lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa
• http://www.nmpa.gov.cn/